Catalyst Biosciences, Inc. CBIO
We take great care to ensure that the data presented and summarized in this overview for CATALYST BIOSCIENCES, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CBIO
View allLatest Institutional Activity in CBIO
Top Purchases
Top Sells
About CBIO
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.
Insider Transactions at CBIO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 16
2025
|
Thomas Wilson Eastling |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.93 P/Share
|
|
Mar 27
2025
|
Weiguo Ye Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
150,000
+18.75%
|
$0
$0.75 P/Share
|
|
Mar 26
2025
|
Weiguo Ye Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
200,000
+28.57%
|
$0
$0.75 P/Share
|
|
Mar 24
2025
|
Weiguo Ye Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
300,000
+50.0%
|
$0
$0.75 P/Share
|
|
Mar 21
2025
|
Songjiang Ma President |
SELL
Open market or private sale
|
Indirect |
174
-0.01%
|
$1,740
$10.0 P/Share
|
|
Mar 20
2025
|
Songjiang Ma President |
SELL
Open market or private sale
|
Indirect |
2,000
-0.07%
|
$20,000
$10.09 P/Share
|
|
Mar 19
2025
|
Songjiang Ma President |
SELL
Open market or private sale
|
Indirect |
2,000
-0.07%
|
$20,000
$10.13 P/Share
|
|
Mar 18
2025
|
Songjiang Ma President |
SELL
Open market or private sale
|
Indirect |
242
-0.01%
|
$2,420
$10.24 P/Share
|
|
Mar 17
2025
|
Songjiang Ma President |
SELL
Open market or private sale
|
Indirect |
2,000
-0.07%
|
$24,000
$12.09 P/Share
|
|
Mar 14
2025
|
Songjiang Ma President |
SELL
Open market or private sale
|
Indirect |
2,000
-0.07%
|
$24,000
$12.31 P/Share
|
|
Mar 13
2025
|
Songjiang Ma President |
SELL
Open market or private sale
|
Indirect |
2,000
-0.07%
|
$22,000
$11.8 P/Share
|
|
Mar 12
2025
|
Songjiang Ma President |
SELL
Open market or private sale
|
Indirect |
2,000
-0.07%
|
$22,000
$11.74 P/Share
|
|
Mar 11
2025
|
Songjiang Ma President |
SELL
Open market or private sale
|
Indirect |
2,000
-0.07%
|
$22,000
$11.4 P/Share
|
|
Mar 10
2025
|
Songjiang Ma President |
SELL
Open market or private sale
|
Indirect |
2,000
-0.07%
|
$20,000
$10.14 P/Share
|
|
Mar 07
2025
|
Songjiang Ma President |
SELL
Open market or private sale
|
Indirect |
2,000
-0.02%
|
$22,000
$11.77 P/Share
|
|
Mar 06
2025
|
Songjiang Ma President |
SELL
Open market or private sale
|
Indirect |
2,000
-0.07%
|
$20,000
$10.8 P/Share
|
|
Mar 05
2025
|
Songjiang Ma President |
SELL
Open market or private sale
|
Indirect |
2,000
-0.07%
|
$20,000
$10.98 P/Share
|
|
Mar 04
2025
|
Songjiang Ma President |
SELL
Open market or private sale
|
Indirect |
2,000
-0.07%
|
$20,000
$10.86 P/Share
|
|
Mar 03
2025
|
Songjiang Ma President |
SELL
Open market or private sale
|
Indirect |
2,000
-0.07%
|
$22,000
$11.23 P/Share
|
|
Feb 28
2025
|
Songjiang Ma President |
SELL
Open market or private sale
|
Indirect |
2,000
-0.07%
|
$22,000
$11.41 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 668K shares |
|---|
| Open market or private sale | 120K shares |
|---|